Natco Pharma Limited (NATCOPHARM) - Net Assets

Latest as of September 2025: Rs86.54 Billion INR ≈ $935.92 Million USD

Based on the latest financial reports, Natco Pharma Limited (NATCOPHARM) has net assets worth Rs86.54 Billion INR (≈ $935.92 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs104.30 Billion ≈ $1.13 Billion USD) and total liabilities (Rs17.76 Billion ≈ $192.06 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Natco Pharma Limited assets under control for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric Value
Current Net Assets Rs86.54 Billion
% of Total Assets 82.97%
Annual Growth Rate 23.4%
5-Year Change 84.61%
10-Year Change 484.1%
Growth Volatility 30.02

Natco Pharma Limited - Net Assets Trend (2005–2025)

This chart illustrates how Natco Pharma Limited's net assets have evolved over time, based on quarterly financial data. Check tangible net worth ratio of Natco Pharma Limited to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Natco Pharma Limited (2005–2025)

The table below shows the annual net assets of Natco Pharma Limited from 2005 to 2025. For live valuation and market cap data, see NATCOPHARM company net worth.

Year Net Assets Change
2025-03-31 Rs76.12 Billion
≈ $823.24 Million		 +30.06%
2024-03-31 Rs58.53 Billion
≈ $632.99 Million		 -35.94%
2023-03-31 Rs91.37 Billion
≈ $988.18 Million		 +114.31%
2022-03-31 Rs42.64 Billion
≈ $461.09 Million		 +3.40%
2021-03-31 Rs41.23 Billion
≈ $445.93 Million		 +8.95%
2020-03-31 Rs37.85 Billion
≈ $409.30 Million		 +8.41%
2019-03-31 Rs34.91 Billion
≈ $377.54 Million		 +13.49%
2018-03-31 Rs30.76 Billion
≈ $332.66 Million		 +86.04%
2017-03-31 Rs16.53 Billion
≈ $178.81 Million		 +26.87%
2016-03-31 Rs13.03 Billion
≈ $140.94 Million		 +53.13%
2015-03-31 Rs8.51 Billion
≈ $92.04 Million		 +16.15%
2014-03-31 Rs7.33 Billion
≈ $79.24 Million		 +34.68%
2013-03-31 Rs5.44 Billion
≈ $58.84 Million		 +15.25%
2012-03-31 Rs4.72 Billion
≈ $51.05 Million		 +33.55%
2011-03-31 Rs3.53 Billion
≈ $38.23 Million		 +13.78%
2010-03-31 Rs3.11 Billion
≈ $33.60 Million		 +16.77%
2009-03-31 Rs2.66 Billion
≈ $28.77 Million		 +18.21%
2008-03-31 Rs2.25 Billion
≈ $24.34 Million		 +20.99%
2007-03-31 Rs1.86 Billion
≈ $20.12 Million		 +20.93%
2006-03-31 Rs1.54 Billion
≈ $16.64 Million		 +35.36%
2005-03-31 Rs1.14 Billion
≈ $12.29 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Natco Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 96107.9% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component Amount Percentage
Retained Earnings Rs62.47 Billion 82.12%
Common Stock Rs358.00 Million 0.47%
Other Components Rs13.25 Billion 17.41%
Total Equity Rs76.07 Billion 100.00%

Natco Pharma Limited Competitors by Market Cap

The table below lists competitors of Natco Pharma Limited ranked by their market capitalization.

Company Market Cap
DRDGOLD Limited
JSE:DRD
 $1.78 Billion
Zhejiang Weixing Industrial Development Co Ltd
SHE:002003
 $1.78 Billion
Luoyang Xinqianglian Slewing Bearin
SHE:300850
 $1.78 Billion
Jiangsu Toland Alloy Co Ltd
SHE:300855
 $1.78 Billion
China Yuchai International Limited
NYSE:CYD
 $1.78 Billion
Dom Development S.A.
WAR:DOM
 $1.78 Billion
Shenzhen Chipscreen Biosciences Co
SHG:688321
 $1.77 Billion
Zhejiang Dayuan Pumps Ind Co
SHG:603757
 $1.77 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Natco Pharma Limited's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 58,531,000,000 to 76,070,000,000, a change of 17,539,000,000 (30.0%).
  • Net income of 18,854,000,000 contributed positively to equity growth.
  • Dividend payments of 1,078,000,000 reduced retained earnings.
  • Share repurchases of 73,000,000 reduced equity.
  • New share issuances of 73,000,000 increased equity.
  • Other comprehensive income decreased equity by 1,497,000,000.
  • Other factors increased equity by 1,260,000,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Rs18.85 Billion +24.79%
Dividends Paid Rs1.08 Billion -1.42%
Share Repurchases Rs73.00 Million -0.1%
Share Issuances Rs73.00 Million +0.1%
Other Comprehensive Income Rs-1.50 Billion -1.97%
Other Changes Rs1.26 Billion +1.66%
Total Change Rs- 29.97%

Book Value vs Market Value Analysis

This analysis compares Natco Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.16x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 108.25x to 2.16x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-03-31 Rs8.47 Rs916.65 x
2006-03-31 Rs10.88 Rs916.65 x
2007-03-31 Rs13.04 Rs916.65 x
2008-03-31 Rs15.57 Rs916.65 x
2009-03-31 Rs18.48 Rs916.65 x
2010-03-31 Rs21.72 Rs916.65 x
2011-03-31 Rs25.04 Rs916.65 x
2012-03-31 Rs32.45 Rs916.65 x
2013-03-31 Rs34.02 Rs916.65 x
2014-03-31 Rs45.44 Rs916.65 x
2015-03-31 Rs51.09 Rs916.65 x
2016-03-31 Rs75.94 Rs916.65 x
2017-03-31 Rs94.56 Rs916.65 x
2018-03-31 Rs172.65 Rs916.65 x
2019-03-31 Rs188.82 Rs916.65 x
2020-03-31 Rs206.82 Rs916.65 x
2021-03-31 Rs225.85 Rs916.65 x
2022-03-31 Rs233.74 Rs916.65 x
2023-03-31 Rs266.98 Rs916.65 x
2024-03-31 Rs326.09 Rs916.65 x
2025-03-31 Rs424.71 Rs916.65 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Natco Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 24.79%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 42.54%
  • • Asset Turnover: 0.51x
  • • Equity Multiplier: 1.13x
  • Recent ROE (24.79%) is above the historical average (15.71%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 1.37% 1.01% 0.54x 2.53x Rs-98.08 Million
2006 16.09% 14.16% 0.55x 2.08x Rs90.09 Million
2007 16.90% 12.61% 0.69x 1.94x Rs124.32 Million
2008 18.56% 12.36% 0.78x 1.92x Rs186.86 Million
2009 16.97% 10.03% 0.85x 1.99x Rs180.60 Million
2010 15.93% 11.31% 0.78x 1.80x Rs181.44 Million
2011 15.18% 12.23% 0.62x 2.01x Rs182.68 Million
2012 12.65% 11.46% 0.58x 1.92x Rs124.88 Million
2013 13.47% 10.88% 0.61x 2.02x Rs185.15 Million
2014 14.15% 13.90% 0.62x 1.65x Rs301.47 Million
2015 15.91% 18.43% 0.53x 1.64x Rs500.11 Million
2016 12.10% 15.07% 0.57x 1.40x Rs272.67 Million
2017 29.47% 24.06% 0.87x 1.41x Rs3.21 Billion
2018 22.66% 31.87% 0.59x 1.21x Rs3.89 Billion
2019 18.47% 30.77% 0.49x 1.23x Rs2.96 Billion
2020 12.21% 24.06% 0.42x 1.22x Rs834.50 Million
2021 10.70% 21.44% 0.43x 1.16x Rs287.40 Million
2022 3.99% 8.73% 0.38x 1.20x Rs-2.56 Billion
2023 14.68% 26.41% 0.48x 1.16x Rs2.28 Billion
2024 23.72% 34.69% 0.58x 1.18x Rs8.03 Billion
2025 24.79% 42.54% 0.51x 1.13x Rs11.25 Billion

Industry Comparison

This section compares Natco Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $31,170,532,189
  • Average return on equity (ROE) among peers: 18.44%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Natco Pharma Limited (NATCOPHARM) Rs86.54 Billion 1.37% 0.21x $1.78 Billion
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) $923.46 Million 6.27% 1.10x $24.98 Million
Aarti Drugs Limited (AARTIDRUGS) $1.00 Billion 13.75% 2.66x $410.81 Million
Aarti Pharmalabs Limited (AARTIPHARM) $13.86 Billion -0.01% 0.47x $672.35 Million
Abbott India Limited (ABBOTINDIA) $3.05 Billion 19.95% 0.50x $6.40 Billion
Ajanta Pharma Limited (AJANTPHARM) $25.99 Billion 18.00% 0.28x $4.71 Billion
Akums Drugs and Pharmaceutical (AKUMS) $30.64 Billion 11.04% 0.34x $1.15 Billion
Alkem Laboratories Limited (ALKEM) $124.34 Billion 17.42% 0.42x $7.27 Billion
Amrutanjan Health Care Limited (AMRUTANJAN) $2.16 Billion 28.39% 0.27x $162.96 Million
Alembic Pharmaceuticals Limited (APLLTD) $16.01 Billion 44.99% 0.54x $1.76 Billion
Aurobindo Pharma Limited (AUROPHARMA) $93.74 Billion 24.55% 0.73x $10.32 Billion

About Natco Pharma Limited

NSE:NATCOPHARM India Drug Manufacturers - Specialty & Generic
Market Cap
$1.78 Billion
Rs164.18 Billion INR
Market Cap Rank
#6560 Global
#310 in India
Share Price
Rs916.65
Change (1 day)
+0.45%
52-Week Range
Rs792.95 - Rs1206.00
All Time High
Rs1591.09
Categories
Companies in India Drug Manufacturers - Specialty & Generic
About

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; a… Read more